Project Oncology®

Improving CAR T Referrals for Large B-Cell Lymphoma: A Path to Better Collaboration

Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay

Redefining Cancer Care with Functional Precision Medicine

Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma

Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors

Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care

Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting

Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies

Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization

Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring

Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies

Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions

The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease

Balancing Benefits and Risks in Emerging Sickle Cell Therapies

Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks

Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care

Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery

Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden

Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study

Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis

First Results From Cohort 4 of the SunRISe-1 Trial

Trial in Progress: Phase 3 MoonRISe-3 Study

HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

Targeting CD123 in AML: The Latest Therapeutic Advancements

Targeting CD123 in AML: The Latest Therapeutic Advancements

Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies

Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

Navigating a Positive MCED Test and Negative Diagnostic Workup: Real-World Data

Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy

AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy

AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy

Reviewing the Latest Bladder Cancer Practice Guidelines

Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer

Patient Perspectives on Bladder Cancer

Chemotherapy Strategies for Metastatic PDAC

Diagnosis and Management of Metastatic PDAC

Chemotherapy Strategies for Metastatic PDAC

Diagnosis and Management of Metastatic PDAC

Chemotherapy Strategies for Metastatic PDAC

Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care

Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care

Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management

Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management

Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings

Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols

Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings